AstraZeneca pledges $174M to ramp up coronavirus vaccine supply deal with Emergent

With a $174 million manufacturing pact signed Monday, Maryland-based Emergent BioSolutions will help produce bulk drug substance for AstraZeneca and Oxford's adenovirus-based COVID-19 shot starting this year.